Mahale, 134 patient colchicine late treatment study: 7% higher mortality [p=0.83] https://c19p.org/mahale
copied to clipboard
A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599
Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with colchicine treatment in unadjusted results.
|
risk of death, 7.2% higher, RR 1.07, p = 0.83, treatment 11 of 39 (28.2%), control 25 of 95 (26.3%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Mahale et al., 12/31/2020, retrospective, India, South Asia, peer-reviewed, 22 authors, study period 22 March, 2020 - 21 May, 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.